Dr. Paika Podcast

#Zepbound #Tirzepatide #GLP1 #WeightLossJourney #ObesityMedicine

Thinking about moving from Zepbound 10 mg to 12.5 mg? In this video, I fact-check 4 common claims about the 10 to 12.5 step, using the FDA label and the trial data:

12.5 mg is a maintenance dose
If you’ve stalled on 10, going up will restart your weight loss
Higher doses mean worse side effects
You have to get to 15 mg eventually

You’ll learn when it makes sense to stay on 10 and when you might be ready for 12.5. I also cover what the new SURMOUNT-MAINTAIN trial showed, what to do in your first 2 weeks after moving up, and 3 safety notes most people miss.

I’m Dr. Mohammed Paika, board-certified in Internal Medicine and Obesity Medicine.

📘 FREE GLP-1 Diet Cookbook (join my newsletter): https://www.drmohammedpaika.com/newsletter
🎓 GLP-1 Masterclass, now with 4 student tools: https://www.drmohammedpaika.com
🌐 My new website: https://www.paikahealth.com
▶️ Watch next, “When Should You Increase or Decrease Your GLP-1 Dose?”: [LINK]

This video is for education only and is not medical advice. Talk with your prescriber before changing your dose.

⏱️ TIMESTAMPS
0:00 Moving from 10 mg to 12.5 mg
2:20 Claim 1: 12.5 mg is a maintenance dose
3:44 Claim 2: Stalled on 10? Going up will restart weight loss
4:44 How much more does 15 mg actually add?
6:52 Claim 3: Higher doses mean worse side effects
8:55 Claim 4: You have to get to 15 mg eventually
9:37 New data: SURMOUNT-MAINTAIN
11:00 When to stay on 10 mg
11:59 When you might be ready for 12.5 mg
12:49 Your first 2 weeks after moving up
13:50 3 quick safety notes
14:52 Scorecard: all 4 claims
15:44 My take
16:10 GLP-1 Masterclass

📚 REFERENCES

ZEPBOUND (tirzepatide) US Prescribing Information. Eli Lilly and Company; revised 8/2026.
https://uspl.lilly.com/zepbound/zepbound.html
Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. Funded by Eli Lilly.
https://pubmed.ncbi.nlm.nih.gov/35658024/
Horn DB, et al. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. Clin Obes. 2025;15(3):e12734. Post hoc analysis; funded by Eli Lilly.
https://pubmed.ncbi.nlm.nih.gov/39800653/
Horn DB, Aronne LJ, et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN). Lancet. 2026;407(10545):2305-2318. Funded by Eli Lilly.
https://pubmed.ncbi.nlm.nih.gov/42119587/
Gorgojo-Martínez JJ, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2023;12(1):145.
https://pubmed.ncbi.nlm.nih.gov/36614945/
Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from ACLM, ASN, OMA and TOS. Am J Clin Nutr. 2025;122(1):344-367.
https://pubmed.ncbi.nlm.nih.gov/40450457/

Viewer comments shown in this video are public YouTube comments, quoted with names removed. They are personal experiences, not evidence.

What is Dr. Paika Podcast?

Welcome to the Dr. Paika Podcast — where medicine, fitness, and humanity come together.

Hosted by Dr. Mohammed K. Paika, M.D., double board-certified in obesity & internal medicine with close to 20 years of hospital experience, this show dives deep into the science of health, obesity, longevity, and mindset — but with compassion, not complexity.

From hospital medicine to the gym floor, from patient care to personal growth — every episode blends real clinical insight with practical, inspiring stories that help you live better and think deeper.

💡 Topics include:

Obesity & metabolic health

Longevity & fitness

Nutrition & preventive medicine

Doctor insights from close to 20 years in hospitals across the US!

Mindset, mental health, and motivation

🎧 Subscribe for weekly conversations that are honest, empowering, and rooted in science — all from a doctor who believes medicine should heal the mind and body.